Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1993-01-08
1996-12-03
Scheiner, Toni R.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241391, 4241851, 5303879, 5303881, 5303882, 5303887, 53038825, 5303888, 530324, 530325, 530351, 514 12, 514 21, C07K 1624, A61K 3900
Patent
active
055805612
ABSTRACT:
A method for blocking suppression of at least one of the natural killer (NK) and lymphocyte activated killer (LAK) cytotoxicity mechanisms in lymphocytes of cancer patients comprises administering to a cancer patient an agent capable of blocking the cytotoxicity suppressive activities of a peptide capable of inducing a detectable decrease in the structuredness of the cytoplasmic matrix in lymphocytes isolated from a patient with cancer (an SCM-factor peptide) in a quantity sufficient to block suppression of at least one of the natural killer (NK) and lymphocyte activated killer (LAK) cytotoxicity mechanisms. The agent can comprise an antibody or an antisense peptide. The invention also includes pharmaceutical compositions and kits for blocking suppression of cytotoxicity.
REFERENCES:
patent: 4391904 (1983-07-01), Litman et al.
patent: 4444744 (1984-04-01), Goldenberg et al.
patent: 4645738 (1987-02-01), Knowles et al.
patent: 5270171 (1993-12-01), Cercek et al.
McCabe et al (1988) Cancer Res 48:4348-4353.
Rawlins et al (1976) Bri. J. Cancer 34:613-618.
Kashima et al (1985) Nature 313:402-404.
Beutler et al (1986) Nature 320:584-588.
Alberts et al (1983) "The Moleculer Biology of the Cell", Garland Publishing, Inc., New York, p. 213.
Harne et al (1993) Trends in Biotech 11:42-44.
Gregouadis et al (1993) Trends in Biotech. 11:440-442.
American Type Culture Collection Catalogue of Cell Lines and Hyperdomes, 7th edition (1992) R. Hay et al, eds., pp. 129-130.
Chenuios Catalog (1986), pp. 6 and 23.
Intelliginetics Software Sequence Search Comparison, Conducted Nov. 9, 1994. Seq. 1D No. 1 (p. 8), Sq. 1D No. 2 (p. 10), Sq 1D No. 6 (p. 8). Cote et al (1983) Proc. Nat'l. Acad. Sci. 80:2026-2030.
Albein et al (eds.) (1972) "Basic Neuochemistry," Little, Brown, and Company, Boston, pp. 503-509.
Rosenberg et al (1984) Nature 312:77-80.
Cercek et al (1993) Cancer Detect. Prev. 17(3):433-445.
Carrell et al (1982) Nature 298:329-334.
Joding (1983) "Monoclonal Antibodies", Academic Press, Orlando, pp. 56-91, 250-259 & 29 .
Chaitchik et al (1985) Eur. J. Cancer Clin. Oncol. 21(10):1165-1170.
Jaffe (1985) in "Kirk-Othmer Concise Encyclopedia of Chemical Technology", John Wiley & Sons, New York, pp. 1236-1238.
Geuzyme Catalogy (1993), pp. 210-211.
L. Cercek, et al., "Biophysical Differentiation Between Lymphocytes from Healthy Donors, Patients with Malignant Diseases and Other Disorders," Brit. J. Cancer 29:345-352 (1974).
L. Cercek & B. Cercek, "Application of the Phenomenon of Changes in the Structuredness of Cytoplasmic Matrix (SCM) in the Diagnosis of Malignant Disorders: A Review," Europ. J. Cancer 13:903-915 (1977).
L. Cercek & B. Cercek, "Changes in SCM-Responses of Lymphocytes in Mice After Implantation with Ehrlich Ascites Cells," Europ. J. Cancer 17:167-171 (1981).
L. Cercek & B. Cercek, "Changes in the SCM Response Ratio (RR.sub.SCM) After Surgical Removal of Malignant Tissue," Brit. J. Cancer 31:250-251.
L. Cercek & B. Cercek, "Apparent Tumour Specificity with the SCM Test," Brit J. Cancer 31:252-253 (1975).
S. Chaitchik et al., "Tumor Specificity of the SCM Test for Cancer Diagnosis," Eur. J. Cancer Clin. Oncol. 21:1165-1170 (1985).
L. Cercek and B. Cercek, "Effects of Ascorbate Ions on Intracellular Fluorescein Emission Polarization Spectra in Cancer and Normal Proliferating Cells," Cancer Detection and Prevention 10:1-20 (1987).
K. Suzuki and Y. Sasaki, "Studies on Encephalitogenic Fragments of Myelin Protein. IV. Synthesis of Glycine Analogs of Tryptophan-Containing Fragment," Chem. Pharm. Bull. 22:2181-2187 (1974).
A. A. Gershkovich et al., "A Study of the Properties of Synthetic Analogs of the Tryptophan-Containing Fragment 113-121 of the Basic Protein of Myelin," Khim. Prirod. Soedinen, 4:557-565 (1979).
C. M. Deber & M. E. M. Young, "Association of Carbon-13 Enriched Human Encephalitogenic Nonapeptide with a Membrane Surface," J. Biol. Chem. 254 6341-6345 (1979).
C. Blake & B. J. Gould, "Use of Enzymes in Immunoassay Techniques: A Review," Analyst 109:533-547 (1984).
M. Oellerich, "Enzyme-Immunoassay: A Review," J. Clin. Chem. Clin. Biochem. 22:895-904 (1984).
J. L. Marx, "How Cancer Cells Spread in the Body," Science 244:147-148 (1989).
B. W. Hancock & R. C. Rees, "Interleukin-2 and Cancer Therapy," Cancer Cells 2L 29-32 (1990).
J. G. Kaplan & C. Bona, "Proteases as Mitogens: The Effect of Trypsin and Pronase on Mouse and Human Lymphocytes," Exp. Cell Res. 88:388-394 (1974).
Y. Shai et al., "Antisense Peptide Recognition of Sense Peptides: Sequence Simplification and Evaluation of Forces Underlying the Interaction," Biochemistry 28:8804-8811 (1989).
G. Fassina et al., "Recognition Properties of Antisense Peptides to Arg.sup.8 -Vasopressin/Bovine Neurophysin II. Biosynthetic Precursor Sequences," Biochemistry 28:8811-8818 (1989).
M. R. Potter & M. Moore, "Natural Cytotoxic Reactivity of Human Lymphocyte Subpopulations," Immunology 37:187-194 (1979).
J. L. Marx, "What T Cells See and How They See It," Science 242:863-194 (1979).
W. Becker, "Determination of Antisera Titres Using the Single Radial Immunodiffusion Method," Immunochemistry 6:539-546 (1969).
R. W. Carrell et al., "Structure and Variation of Human .alpha..sub.1 -Antitrypsin," Nature 298:329-334 (1982).
M. Fagerhol & D. W. Cox, "The Pi Polymorphism; Genetic, Biochemical, and Clinical Aspects of Human .alpha..sub.1 -Antitrypsin," Advances in Human Genetics (H. Harris and K. Hirschhorn, eds., Plenum Press, New York, 1981), vol. 11, pp. 1-62.
W. Troll, M. S. Meyn & T. G. Rossman, "Mechanisms of Protease Action in Carcinogenesis," in Carcinogenesis--A Comprehensive Survey, vol. II; Mechanisms of Tumor Promotion and Cocarcinogenesis (T. J. Slaga et al., eds., Raven Press, New York 1978), pp. 301-312.
T. G. Rossman & W. Troll, "Protease Inhibitors in Carcinogenesis: Possible Sites of Action," in Carcinogenesis, vol. V: Modifiers of Chemical Carcinogenesis (T. J. Slaga, ed., Ravel Press, New York, 1980), pp. 127-148.
G. J. Cianciolo, "Anti-Inflammatory Effects of Neoplasia," in Inflammation: Basic Principles and Clinical Correlates (J. I. Gallin et al., eds., Raven Press, New York, 1988), ch. 48, pp. 861-874.
E. Reich, "Tumor-Associated Fibrinolysis," Fed. Proc. 32:2174-2175 (1973).
H. B. Bosmann, "Release of Specific Protease During Mitotic Cycle of L5178Y Murine Leukaemic Cells by Sublethal Autolysis," Nature 249:144-145 (1974).
D. Moscatelli & D. B. Rifkin, "Membrane and Matrix Localization of Proteinases: A Common Theme in Tumor Cell Invasion and Angiogenesis," Biochim. Biophys. Acta 948:67-85 (1988).
B. Hagmar et al., "Why Do Tumors Metastasize? An Overview of Current Research," Tumor Biol, 5:141-149 (1984).
C. A. McWherter et al., "Novel Inhibitors of Human Leukocyte Elastase and Cathepsin G. Sequence Variants of Squash Seed Protease Inhibitor with Altered Protease Selectivity," Biochemistry 28:5708-5714 (1989).
D. C. Linch et al., "Signal Transduction in Human T Lymphocytes," Immunol. Rev. 95:137-159 (1987).
G. L. Nicolson, "Cancer Metastasis: Tumor Cell and Host Organ Properties Important in Metastasis to Specific Secondary Sites," Biochim. Biophys. Acta 948:175-224 (1988).
M. S. Bernatowicz & G. R. Matsueda, "Preparation of Peptide-Protein Immunogens Using N-Succinimidyl Bromoacetate as a Heterobifunctional Crosslinking Reagent," Anal. Biochem. 155:95-102 (1986).
E. Harlow & D. Lane, "Antibodies: A Laboratory Manual" (Cold Spring Harbor, New York, 1988), ch. 5, pp. 53-137.
J. W. Goding, "Monoclonal Antibodies: Prinicples and Practice" (Academic Press, London, 2d ed., 1986), pp. 59-141.
P. Tijssen, "Practice and Theory of Enzyme Immunoassays" (Elsevier, Amsterdam, 1985), pp. 297-314.
C. Wittekind et al., "Localization of CEA, HCG, Lysozyme, Alpha-1-Antitrypsin, and Alpha-1-Antichymotrypsin in Gastric Cancer and Prognosis," Virchows Arch. A: 409:715-724 (1986).
H. Kataoka et al., "Neutral Proteinases and Inhibitors Secreted by Human Rectal Adenocarcinoma Cell Line (RCM-1)," Invasion Metastasis 9:149-166 (1989).
H. Kataoka et al., "New Human Colorectal Carcinoma Cell Lines That Secret Proteinase Inhibitors in Vitro,
Cercek Boris
Cercek Lea
LandOfFree
Methods and pharmaceutical compositions for blocking suppression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and pharmaceutical compositions for blocking suppression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and pharmaceutical compositions for blocking suppression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-783309